-
The FDA has approved a new, highly selective alpha-1 adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia (BPH).
-
The American College of Physicians has just published a new clinical practice guideline on the use of second-generation antidepressants in treating depressive disorders.
-
The syllogistic process that led us all to accept the utility of ASA in prevention of CVD in diabetics seemed innocent enough: a) ASA reduces CV events in persons with CVD, and b) diabetes is considered a CV risk equivalent; therefore, c) ASA must reduce CV events in persons with diabetes.
-
In this issue: The JUPITER trial causes a stir; ACP practice guideline for antidepressant use; testosterone for low libido; continued shortage of Hib vaccine; FDA Actions.
-
Hospital-acquired pneumonia (HAP) represents the second most common nosocomial infection, accounting for 15% of all hospital-associated infections.
-
-
-
An outbreak of 140 human cases of West Nile Virus in Kern County, California (better known for its increased risk of coccidioidomycosis), during the summer of 2007, prompted Reisen et al to look for possible causes.
-
Most of us microbiologists were rudely awakened to the insufficiency of our susceptibility testing methods last year when the College of American Pathologists (CAP) sent out a carbapenemase-producing Klebsiella pneumoniae as an unknown proficiency testing sample. My laboratory, like most others in the United States, incorrectly reported the isolate as susceptible to imipenem and meropenem.
-
Patients enrolled in the swiss hiv cohort study, initiating their first cART regimen between 1996 and early 2007, who had baseline and follow up CD4+ count and HIV RNA data available, were included in the analysis.